| Product Name | Tertiapin LQ |
|---|---|
| Description |
Tertiapin LQ is a selective blocker of Kir1.1 channels, obtained by modifying tertiapin, the toxin from the honey bee venom. Tertiapin LQ blocks Kir1 with high affinity (1.1 nM) and high selectivity (>250-fold) over many commonly studied Kir subtypes. Application of tertiapin LQ locally in the superficial layers of the cerebellar cortex in decerebrate ferrets suppresses normal performance of Purkinje cell pause responses to the conditional stimulus with no detectable effect on spontaneous firing. |
| Synonyms | TPNLQ, TLQ |
| Molecular Weight | 2428.03 Da |
| Target | Potassium channels |
| Amino Acid Sequence | ALCNCNRIIIPLQCWKKCGKK-NH2 |
| Form | Freeze dried solid |
| Purity | >95% by hplc |
| Storage | Store dry, frozen and in the dark |
| Notes | Modifications: Disulfide bridges between cysteines 3 - 14, and 5 - 18, C-terminal amide |
| References |
Ramu et al (2008) Engineered specific and high-affinity inhibitor for a subtype of inward-rectifier K+ channels. Proc.Natl.Acad.Sci.USA 105 10774 PMID: 18669667Estrada and Kaufman (2018) µ-Opioid receptors inhibit the exercise pressor reflex by closing N-type calcium channels but not by opening GIRK channels in rats. Am J Physiol Regul Integr Comp Physiol. 314(5) R693 PMID: 29341826Johansson and Hesslow (2020) Kir3 channel blockade in the cerebellar cortex suppresses performance of classically conditioned Purkinje cell responses. Sci Rep 10 15654 PMID: 32973240Pubchem entry for tertiapin LQ Related areas All peptides >All potassium channel modulators >All neuroscience research categories > |
| Supplier | Isca Biochemicals Limited |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
